The U.K. | The U.K. pharma marketing watchdog has slammed AGB Pharma for misleadingly implying a lack of fertility considerations for its melatonin medicine, Adaflex.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Pfizer’s complaint about Alnylam’s activities at a cardiology congress has led the PMCPA to chastise the | Pfizer’s complaint…
Following an inspection earlier this year that yielded a Form 483, Indian generics juggernaut Alembic Pharmaceuticals has…
The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading…
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. |…
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended…
The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) and the U.S. | The program looks to support…
